Dirk Scharn
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.
Journal: Cancer discovery
Published: March 12, 2024
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Journal: Nature cancer
Published: July 27, 2021
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors.
Journal: Journal of medicinal chemistry
Published: November 06, 2019
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Journal: Molecular cancer therapeutics
Published: August 12, 2019
Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.
Journal: Journal of medicinal chemistry
Published: September 12, 2018
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Journal: Oncogene
Published: July 21, 2017
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
Journal: Cell reports
Published: March 10, 2017
Bispyrimidines as potent histamine H(4) receptor ligands: delineation of structure-activity relationships and detailed H(4) receptor binding mode.
Journal: Journal of medicinal chemistry
Published: May 15, 2013
Detailed structure-activity relationship of indolecarboxamides as H4 receptor ligands.
Journal: European journal of medicinal chemistry
Published: March 16, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026